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Osteoblasts paradoxically secrete the
main constituent of the bone matrix
before turning on their master
differentiation gene Runx2. These cells
are addicted to glucose, whose uptake
coordinates osteoblast differentiation
and bone formation through crosstalk
with Runx2, revealing a key regulatory
role for metabolic demand.
ArticleGlucose Uptake and Runx2 Synergize
to Orchestrate Osteoblast Differentiation
and Bone Formation
Jianwen Wei,1,4 Junko Shimazu,1,4 Munevver P. Makinistoglu,1 Antonio Maurizi,1 Daisuke Kajimura,1 Haihong Zong,2
Takeshi Takarada,3 Takashi Iezaki,3 Jeffrey E. Pessin,2 Eiichi Hinoi,3 and Gerard Karsenty1,*
1Department of Genetics and Development, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
2Department of Medicine and Molecular Pharmacology, The Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA
3Faculty of Pharmacy, Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa




The synthesis of type I collagen, themain component
of bone matrix, precedes the expression of Runx2,
the earliest determinant of osteoblast differentia-
tion. We hypothesized that the energetic needs of
osteoblasts might explain this apparent paradox.
We show here that glucose, themain nutrient of oste-
oblasts, is transported in these cells through Glut1,
whose expression precedes that of Runx2. Glucose
uptake favors osteoblast differentiation by suppress-
ing the AMPK-dependent proteasomal degradation
of Runx2 and promotes bone formation by inhibiting
another function of AMPK. While RUNX2 cannot
induce osteoblast differentiation when glucose up-
take is compromised, raising blood glucose levels re-
stores collagen synthesis in Runx2-null osteoblasts
and initiates bone formation in Runx2-deficient em-
bryos. Moreover, RUNX2 favors Glut1 expression,
and this feedforward regulation between RUNX2
and Glut1 determines the onset of osteoblast differ-
entiation during development and the extent of
bone formation throughout life. These results reveal
an unexpected intricacy between bone and glucose
metabolism.
INTRODUCTION
The transcription factor RUNX2 is a master determinant of oste-
oblast differentiation (Long, 2012; Karsenty et al., 2009). Its
expression in prospective osteoblasts precedes osteoblast dif-
ferentiation; its inactivation prevents osteoblast differentiation;
and its haplo-insufficiency causes a skeletal dysplasia called
cleidocranial dysplasia (CCD), which is characterized by a delay
in osteoblast differentiation, leading to hypoplastic clavicles and
open fontanelles. Several aspects of Runx2 biology, however,
remain poorly understood. For example, the nature of themolec-
ular events leading to RUNX2 accumulation in cells of the
osteoblast lineage is largely unknown. Another question is to1576 Cell 161, 1576–1591, June 18, 2015 ª2015 Elsevier Inc.determine if and how RUNX2 contributes to bone formation
by differentiated osteoblasts. A peculiar feature of osteoblast
biology raises this latter issue.
Type I collagen is by far the most abundant protein of bone
extracellular matrix (ECM), and its synthesis by osteoblasts is
often considered a biomarker of bone formation. Type I collagen
is a heterotrimeric protein made of two a1(I) chains and one a2(I)
chain, which are encoded by two different genes (Vuorio and de
Crombrugghe, 1990). In vitro, RUNX2 can bind to and upregulate
the activity of an a1(I) Collagen promoter fragment (Kern et al.,
2001). However, in vivo type I collagen synthesis precedes
Runx2 expression in prospective osteoblasts. Thus, the regula-
tion of type I collagen synthesis in osteoblasts is not fully under-
stood, and by extension, since bone ECM is mainly made of
type I collagen, it is also unclear how bone formation by osteo-
blasts is regulated.
Besides being responsible for bone formation, osteoblasts are
endocrine cells that secrete the hormone osteocalcin, which
favors glucose homeostasis (Lee et al., 2007). Notwithstanding
the molecular complexity of this emerging regulation, the identi-
fication of bone as a regulator of glucose metabolism raises a
fundamental question: why would bone have this role? A prereq-
uisite to answering this question is to define the functions of
glucose in osteoblasts.
Here, we asked if the energetic needs of the osteoblast might
explain howosteoblast differentiation andbone formation occurs
in vivo. We found that glucose is the main nutrient of osteoblasts
and it is transported in these cells in an insulin-independent
manner through the facilitative Glut1 glucose transporter whose
expression precedes that of Runx2 during skeletogenesis. By in-
hibiting one activity of AMPK, glucose is necessary for RUNX2
accumulation and osteoblast differentiation; through the inhibi-
tion of another AMPK function, glucose is necessary for collagen
synthesis and bone formation. Moreover, by promoting RUNX2
accumulation, glucose uptake in osteoblasts favors Osteocalcin
expression and whole-body glucose homeostasis. We further
show that RUNX2 is not sufficient for timely osteoblast differenti-
ation and proper bone formation if glucose uptake is compro-
mised, whereas raising blood glucose levels induces collagen
synthesis and bone formation in the absence of Runx2. The
relationship between RUNX2 and glucose uptake is even more
elaborate since RUNX2 is needed for Glut1 expression in osteo-
blasts. This crosstalk between RUNX2 and glucose uptake acts
as an amplification mechanism, allowing osteoblast differentia-
tion and bone formation to be coordinated throughout life. This
study provides a bone-centric illustration of the importance of
crosstalk between bone and glucose metabolism.
RESULTS
Insulin-Independent Glucose Uptake in Osteoblasts
To determine the main nutrient(s) used by osteoblasts, we
measured the oxygen consumption rate (OCR) of osteoblasts
when incubated with individual nutrients. Like neurons and un-
like myoblasts, osteoblasts had the highest OCR when cultured
in the presence of glucose and the lowest when cultured in the
presence of a representative fatty acid (Figure 1A). These results
prompted us to measure, through euglycemic hyperinsulinemic
clamps, the amount of glucose taken up by bone and the mech-
anism by which it occurs in 3-month-old wild-type (WT) mice.
In the conditions of this assay, bone takes up one-fifth of the
quantity of glucose taken up by skeletal muscle, the tissue taking
up the majority of glucose in the mouse (Ferrannini et al., 1988),
and one-half of what is taken up by white adipose tissue (WAT)
(Figure 1B). Unlike uptake for skeletal muscle and WAT, glucose
uptake in bone is not enhanced by insulin (Figure 1B). We also
compared the uptake of 2-[U-14C] deoxyglucose (2-DG) in
osteoblasts and osteoclasts to that in myoblasts. Both bone
cell types take up approximately one-third of the quantity of
2-DG taken up bymyoblasts and do so in an insulin-independent
manner (Figure 1C). Consistent with these observations, Glut1,
which transports glucose in an insulin-independent manner,
is expressed two orders of magnitude higher than any other
class I glucose transporter in bone cells (Figure 1D). The rest of
this study focuses on the functions of glucose in osteoblasts.
To establish the biological importance of Glut1 expression in
these cells, we analyzed osteoblasts lacking or overexpressing
modestly (1.75-fold) Glut1 (Figures S1A and S1B). Glut1/
osteoblasts took up 75% less 2-DG, and a1(I)Col-Glut1 osteo-
blasts took up 20% more 2-DG than did control osteoblasts
(Figure 1E). Consequently, glycogen content was decreased
50% in Glut1/ and increased 40% in a1(I)Col-Glut1 osteo-
blasts compared to controls (Figure S1C). Thus, GLUT1 is
responsible for the majority of glucose uptake in osteoblasts.
Glucose Uptake Is Necessary for Osteoblast
Differentiation during Development
Next, we analyzed the spatial and temporal pattern of Glut1
expression during skeletogenesis by in situ hybridization and
compared it to that of a1(I) Collagen and Runx2, two marker
genes of mesenchymal cells and osteoblasts, of a1(II) Collagen,
a marker of non-hypertrophic chondrocytes, and of a1(X)
collagen, a marker of hypertrophic chondrocytes.
At E10.5Glut1 is highly expressed in a1(I) Collagen-expressing
mesenchymal cells of the developing hindlimbs (Figures 1Fa–
1Fj). Runx2 is expressed in a1(I) Collagen/Glut1-expressing cells
at E12.5 and is expressed in these cells throughout development
(Figures 1Fk–1Fo). Prior to E12.5, another Runx gene, Runx1, is
expressed in a1(I) Collagen/Glut1-expressing cells (Figures 1Fp–1Ft). The third Runx gene, Runx3, is not expressed before E13.5,
and its expression is predominant in a1(II) Collagen-expressing
chondrocytes (Figures 1Fu–1Fy and 1Fz–1Fb1). Glut1 is virtually
not expressed in chondrocytes (Figures 1Fa–1Fe and 1Fz–1Fe1).
In view of this pattern of expression, we analyzed the function
of Glut1 during osteoblast differentiation by crossing mice
harboring a floxed allele ofGlut1 (Figure S2A) with mice express-
ing the Cre recombinase under the control of Dermo1 (Yu et al.,
2003) (Glut1dermo1/), which deletes genes starting at E12.5, or
of Osterix regulatory elements (Rodda and McMahon, 2006)
(Glut1osx/), which deletes genes starting at E14.5. We verified
in each case that Glut1 was efficiently deleted in the targeted
cells, but not in other cell types or tissues, and that expression
of other Gluts was not affected by the Glut1 deletion (Figures
S2B–S2E).
Using alcian blue/alizarin red staining of skeletal preparations
to distinguish non-mineralized (blue) frommineralized ECM (red),
Glut1dermo1/ and control embryos were indistinguishable until
E13.5 (Figure S2F). E14.0 was the first time point at which a delay
in ECM mineralization in long bones and the jaws was seen in
Glut1dermo1/ embryos (Figure 2A). This difference in ECM
mineralization between control and Glut1dermo1/ embryos
was verified histologically (Figure 2B). At E14.5, ECMmineraliza-
tion was still absent in the mandibles ofGlut1dermo1/ embryos
(Figure 2A). Beyond E14.5, we also studied Glut1osx/ em-
bryos. At E15.5, a large area of mineralized ECM was present
in the axial skeleton of controls, but not in that of Glut1osx/
and Glut1dermo1/ embryos, except in long bones (Figures
2C and S2F). Von Kossa staining of histological sections de-
tected extensive ECM mineralization in skeletal elements of
control embryos, while this mineralization was more restricted
in Glut1osx/ embryos; alcian blue staining of these sections
showed that ECM in Glut1osx/ skeletal elements was mostly
of cartilaginous nature (Figure 2D). Consistent with this observa-
tion, a1(X) Collagen-expressing hypertrophic chondrocytes
covered a larger area in Glut1osx/ than in control skeletal
elements, and expression of Osteocalcin was undetectable in
Glut1osx/ skeletal elements (Figure 2E), indicating that osteo-
blast differentiation was delayed in E15.5 Glut1osx/ embryos.
Remarkably, despite these delays in osteoblast differentiation
and bone formation, Runx2 and a1(I) Collagenwere normally ex-
pressed in E15.5 Glut1osx/ skeletal elements (Figure 2E).
At E18.5, Glut1osx/ embryos’ skulls, which ossify mostly
through an intramembranous process, were poorly mineralized,
suggesting thatosteoblastdifferentiationwasdelayed(Figure2F).
Von Kossa staining of histological sections showed numerous
long, thick trabeculae in controls, but not in Glut1osx/, long
bones, and an alcian blue staining showed many more cartilagi-
nous remnants in Glut1osx/ than in control skeletal elements
(Figure 2G). Accordingly, the area occupied by a1(X) Collagen-
expressing hypertrophic chondrocytes remained larger in
Glut1osx/ than in control skeletal elements, and expression
of Osteocalcin was still barely detectable (Figures 2H–2J). This
incomplete osteoblast differentiation in Glut1osx/ bones and
osteoblasts was further illustrated by the decreased expression
of Bsp (Figures 2I and 2J). This delay in osteoblast differentiation
explains why E18.5 Glut1osx/ embryos had open fontanelles
and hypoplastic clavicles (Figure 2F). Even though these twoCell 161, 1576–1591, June 18, 2015 ª2015 Elsevier Inc. 1577
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Figure 1. Insulin-Independent Glucose Uptake in Osteoblasts
(A) Oxygen consumption rate (OCR) of osteoblasts, C2C12 myoblasts, or hippocampal neurons incubated with vehicle, 10 mM glucose, 2 mM glutamine, or
300 mM palmitate in 13 Krebs-Henseleit buffer for 2 hr (n = 8).
(B) Glucose uptake measured by euglycemic hyperinsulinemic clamps in femurs, white adipose tissue, and gastrocnemius muscle of WT mice before or after
insulin infusion (2.5 mU/kg/min) (n = 4).
(C) Uptake rate of 2-DG in osteoblasts (Osb), osteoclasts (Ocl), and myoblasts (n = 3).
(D) Expression of class I Gluts in osteoblasts and osteoclasts assayed by qPCR.
(E) Uptake rate of 2-DG in Glut1fl/fl, Glut1/, WT, and a1(I)Col-Glut1 osteoblasts (n = 6–8).
(F) In situ hybridization analysis of Glut1 (a–e), a1(I) Collagen (f–j), Runx2 (k–o) Runx1 (p–t), Runx3 (u–v), a1(II) Collagen (z–b1), and a1(X) Collagen (c1–e1) in
hindlimbs during embryonic development.
All error bars represent SEM.
See also Figure S1.
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Figure 2. Glucose Uptake Is Necessary for Osteoblast Differentiation during Development
(A) Alcian blue/alizarin red staining of skeletal preparations of E14.0 and 14.5 Glut1dermo1/ and Glut1fl/fl embryos.
(B) Von Kossa staining of skull sections of E14.5 Glut1dermo1/ and Glut1fl/fl embryos.
(C) Alcian blue/alizarin red staining of skeletal preparations of E15.5 Glut1osx/, Glut1fl/fl, and Osx-cre embryos.
(D) Von Kossa or alcian blue staining of femur from E15.5 Glut1osx/, Glut1fl/fl, and Osx-cre embryos.
(E) In situ hybridization analysis of Osteocalcin, a1(I), a1(X) Collagen, and Runx2 expression in E15.5 Glut1osx/ and Glut1fl/fl femurs.
(legend continued on next page)
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features are characteristic of CCD, a disease caused by the
decreased function of RUNX2 (Mundlos et al., 1997; Lee et al.,
1997),Runx2expressionwasnormal inE18.5Glut1osx/bones.
The samewas true for a1(I) Collagen expression (Figures 2H–2J).
Accounting for this delay in osteoblast differentiation and CCD
phenotype, there was a 70% decrease in RUNX2 accumulation
in E18.5 Glut1osx/ bones and osteoblasts (Figure 2K). This
decrease in RUNX2 accumulation was not observed for other
transcription factors (Figure S2G). There was also a 70%
decrease in type I collagen accumulation in E18.5 Glut1/
bones and osteoblasts because of a 60% decrease in the rate
of collagen synthesis in Glut1/ compared to control osteo-
blasts (Figures 2K and 2L). This latter finding explained the
decreased bone formation in Glut1osx/ embryos. Of note,
Chrebp, a transcriptional mediator of glucose signaling in other
cell types (Yamashita et al., 2001), is not expressed and does
not regulate glucose uptake in osteoblasts (Figures S2H–S2K).
Glucose Uptake in Osteoblasts Is Necessary for Bone
Formation and Whole-Body Glucose Homeostasis
Post-natally
To studyGlut1 functions in osteoblasts post-natally, we crossed
Glut1fl/fl mice with Osteocalcin-Cre mice (Glut1ocn/) that do
not initiate gene deletion before E18.5 (Zhang et al., 2002) and
performed an inducible deletion of Glut1 in osteoblasts in
6-week-oldOsx-Cre;Glut1fl/flmice (Glut1Dox/). After verifying
the specificity and efficiency of the gene deletions (Figures S3A
and S3B), we examined both models of Glut1/ mice at
3 months of age and included in this analysis a1(I)Col-Glut1
mice that modestly overexpress (1.75-fold) Glut1 in osteoblasts
(Figure S2D).
Glut1ocn/ and Glut1Dox/ mice of either sex presented
with a low bone mass in all bones analyzed, whereas a1(I)Col-
Glut1mice displayed a high bone mass. In these mouse models,
only the parameters of bone formation, i.e., circulating levels of
PINP, mineral apposition rate, bone formation rate, and number
of osteoblasts, were affected (Figures 3A–3C and S3C–S3E).
Expression of the cell-cycle regulators Ccnd2, Ccne1, and
Cdk4 and osteoblast proliferation as measured by bromodeox-
yuridine (BrdU) incorporation were decreased in Glut1ocn/
and increased in a1(I)Col-Glut1 bones (Figures 3D and 3E).
Again, accumulation, and not expression, of RUNX2 and type I
collagen was decreased in Glut1ocn/ and increased in a1(I)
Col-Glut1 bones (Figures 3F and 3G).
Following fluctuating RUNX2 accumulation, expression of Os-
teocalcin, a RUNX2 target gene, and circulating osteocalcin
levels were low in Glut1ocn/ mice and high in a1(I)Col-Glut1
compared to control mice (Figures 3F and S3F). As a result,(F) Alcian blue/alizarin red staining of skeletal preparations of E18.5 Glut1osx/
(G) Von Kossa or alcian blue staining of femur from E18.5 Glut1osx/, Glut1fl/fl
(H) In situ hybridization analysis of Osteocalcin, a1(I), a1(X) Collagen, and Runx2
(I) Expression of osteoblast markers in E18.5 Glut1osx/ and Glut1fl/fl femurs (n
(J) Expression of osteoblast marker genes in Glut1fl/fl and Glut1/ osteoblasts
(K) a1(I) Collagen and RUNX2 accumulations in E18.5 Glut1osx/ and Glut1fl/fl
(L) 3H-proline incorporation into collagen of Glut1fl/fl and Glut1/ osteoblasts (
All error bars represent SEM.
See also Figure S2.
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measured by a glucose tolerance test, insulin sensitivity as-
sessed by an insulin tolerance test (ITT), and the steady-state
glucose infusion rate during euglycemic-hyerpinsulinemic clamp
were suppressed in Glut1ocn/mice and improved in a1(I)Col-
Glut1 compared to control mice (Figures 3H–3N). In summary,
glucose uptake in the cells of the osteoblast lineage is necessary
for osteoblast differentiation, bone formation, and whole-body
glucose homeostasis.
Glucose Uptake Favors Osteoblast Differentiation and
Bone Formation by Inhibiting AMPK
To determine if the delay in osteoblast differentiation and the
decrease in bone formation seen in Glut1osx/ embryos and
mice were due to a decrease in protein synthesis that a poor
glucose uptake triggers (Jeyapalan et al., 2007; Mayer et al.,
2011), we measured AMP, ADP, and ATP contents in Glut1/
osteoblasts.
Although AMP and ATP levels were not affected, there was a
3-fold increase in ADP content, leading to a 3-fold increase in
the ratio of ADP to ATP in Glut1/ versus control osteoblasts
(Figures 4A and S4A). As a result, AMPK activity, assessed by
the phosphorylation of its a subunit at Thr172 and of its substrate
ACC1 at Ser79 (Woods et al., 1994; Wilson et al., 1996), was
increased (Figure 4B). Several lines of evidence indicated that
the activity of the mTORC1 complex was decreased inGlut1/
osteoblasts. Phosphorylation of the mTORC1 substrates
p70S6K at Thr389, 4E-BP1 at Thr37, and eIF4G at Ser1108
was decreased (Bolster et al., 2002; Reiter et al., 2005) (Fig-
ure 4C); Raptor phosphorylation at Ser792 was increased; and
mTORC1 kinase activity was decreased inGlut1/ osteoblasts
(Figures 4B and 4D). Conversely, p70S6K phosphorylation and
collagen accumulation were both decreased in Raptor/ oste-
oblasts, and knockdown of Tsc1 and Tsc2 not only restored
mTORC1 activity as measured by p70S6K phosphorylation but
also normalized collagen accumulation in Glut1/ osteoblasts
(Figures 4E and 4F).
To demonstrate that the decrease in mTORC1 activity and the
phenotypes of the Glut1osx/ mice are caused by an increase
in AMPK activity in osteoblasts, we decreased the expression of
Ampk in osteoblasts by generating Glut1/ embryos or mice
lacking in osteoblasts one allele of Ampka1, the most highly
expressed AMPKa subunit in these cells (Figure 4G). Phos-
phorylation of AMPKa1 and p70S6K, ATP contents, RUNX2,
and type I collagen accumulations were similar in Glut1osx/;
Ampka1osx+/ and control osteoblasts, indicating that AMPK
activity and therefore mTORC1 signaling had been restored in
Glut1osx/;Ampka1osx+/ osteoblasts (Figures 4H, S4B, and, Glut1fl/fl, and Osx-cre embryos.
, and Osx-cre embryos.
expression in E18.5 Glut1osx/ and Glut1fl/fl femurs.
= 9).
(n = 6).
femurs and Glut1fl/fl and Glut1/ osteoblasts.
n = 6).
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Figure 3. Glucose Uptake in Osteoblasts Is Necessary for Bone Formation and Glucose Homeostasis Post-natally
(A and B) Histomorphometric analysis of L4 vertebrae of 3-month-old Glut1fl/fl, Glut1ocn/, WT, and a1(I)Col-Glut1 male mice (n = 9–11).
(C) mCT analysis of proximal femurs of Glut1fl/fl and Glut1ocn/ male mice (n = 7).
(D) Expression of Ccnd2, Ccne1, and Cdk4 in femurs of 3-month-old Glut1fl/fl, Glut1ocn/, WT, and a1(I)Col-Glut1 mice (n = 6).
(E) BrdU incorporation in calvaria of P14 Glut1fl/fl, Glut1ocn/, WT, and a1(I)Col-Glut1 mice (n = 5–8).
(legend continued on next page)
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S4C). As a result, alcian blue/alizarin red staining of skeletal
preparations, histological, and in situ hybridization analyses
showed normal osteoblast differentiation and no evidence of
CCD in Glut1osx/;Ampka1osx+/ embryos (Figures 4I–4L).
Bone formation parameters were also normal in Glut1ocn/;
Ampka1ocn+/ mice (Figure 4M).
Two experiments showed that increasing AMPK activity in os-
teoblasts is deleterious for bone. Treating mouse osteoblasts
with AICAR, an AMPK agonist, profoundly decreased type I
collagen and RUNX2 accumulations in these cells, and WT
mice treatedwith AICAR from 6 to 14weeks of age showed a sig-
nificant decrease in bone formation parameters and bone
mass (Figures 4N and 4O). Accordingly, and as is the case for
Glut1/ osteoblasts, WT osteoblasts deprived of glucose
had higher levels of P-AMPK and lower levels of P-P70S6K
and type I collagen than if cultured in the presence of glucose
(Figure S4D).
Runx2 Cannot Induce Osteoblast Differentiation when
Glucose Uptake Is Hampered
In the course of these experiments, we noticed that RUNX2
accumulation was restored when Glut1/ osteoblasts were
treated with an inhibitor of proteasome degradation and that
RUNX2 ubiquitination was increased in Glut1/ osteoblasts
(Figure 5A). Normal RUNX2 ubiquitination in Glut1/;
Ampka1+/ and Glut1/;Ampka1/ osteoblasts (Figure 5B)
implicated AMPK in RUNX2 polyubiquitination. Mass spectrom-
etry and bioinformatics analyses identified a possible AMPK
recognition site in SMURF1, an E3 ubiquitin ligase involved in
RUNX2 degradation (Zhao et al., 2003) (Figures S5A and S5B).
In vitro, AMPK phosphorylated SMURF1 at Ser148, and this
phosphorylation event was needed for SMURF1-induced
RUNX2 ubiquitination (Figures 5C and 5D). SMURF1 phosphor-
ylation at Ser148 did not increase in Ampka1/ osteoblasts,
and RUNX2 accumulation did not decrease in Ampka1/ or
Smurf1/ osteoblasts cultured in the absence of glucose as
it did in WT osteoblasts (Figures 5E and 5F). Moreover, an anti-
phospho-SMURF1 antibody demonstrated AMPKa1 interaction
with phospho-SMURF1 in Glut1/ osteoblasts and that
SMURF1 phosphorylation at S148 was higher in Glut1/ than
in control, Glut1/;Ampka1+/, and Glut1/;Ampka1/
osteoblasts (Figures 5G and 5H). These results indicate that
AMPK favors RUNX2 proteasomal degradation by phosphory-
lating SMURF1.
This unanticipated regulation of RUNX2 ubiquitination by
AMPK allowed selectively assessing the ability of RUNX2 to
induce osteoblast differentiation when glucose uptake is
compromised. This was achieved by generating Glut1osx/(F) Expression of osteoblast marker genes in the femurs of 3-month-old Glut1fl/fl
(G) a1(I) Collagen and RUNX2 accumulations in the femurs of 3-month-old Glut1
(H and I) Glucose-stimulated insulin secretion in 3-month-old Glut1fl/fl, Glut1ocn
(J and K) Glucose tolerance test in 3-month-old Glut1fl/fl, Glut1ocn/, WT, and
(L) ITT in 3-month-old Glut1fl/fl, Glut1ocn/, and WT mice (n = 8–10).
(M) Glucose infusion rate in 3-month-old Glut1fl/fl and Glut1ocn/ mice (n = 6).
(N) ITT in 3-month-old WT and a1(I)Col-Glut1 mice (n = 8–10).
All error bars represent SEM.
See also Figure S3.
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This manipulation normalized RUNX2 accumulation but did
not restore mTORC1 signaling since p70S6K phosphorylation
and type I collagen synthesis remained low in Glut1osx/;
Smurf1+/ osteoblasts (Figures 5I and 5J). As a result, and
despite a normal accumulation of RUNX2, skeletal development
was equally delayed inGlut1osx/;Smurf1+/ andGlut1osx/
embryos at E15.5 and E18.5 (Figures 5K and 5L). The cartilagi-
nous area and the zone of a1(X)Col-expressing cells were as
enlarged in Glut1osx/;Smurf1+/ embryos as in Glut1osx/
embryos (Figures 5M and 5N). Hence, RUNX2 cannot induce
proper osteoblast differentiation during embryogenesis if
glucose uptake is hampered because protein synthesis is
decreased (Figure 5O). Likewise, Glut1ocn/;Smurf1+/ mice
were as osteopenic as Glut1ocn/ mice (Figure S5C).
Glucose Can Initiate Bone Formation in
Runx2-Deficient Embryos
Next, we asked if conversely, raising the extracellular concentra-
tion of glucose was sufficient to initiate type I collagen synthesis
in Runx2-deficient osteoblasts. To that end, Runx2fl/fl osteo-
blasts (Takarada et al., 2013) were infected with a Cre-express-
ing adenovirus (Figure S6A); these Runx2-/- osteoblasts were
then cultured in a differentiation medium containing either 5 or
10 mM glucose.
In Runx2/ osteoblasts cultured in the presence of 5 mM
glucose, GLUT1 accumulation and glucose consumption rate
were decreased, phosphorylation of AMPKa1 was high, and
phosphorylation of p70S6K was low, indicating that mTORC1
signaling was inhibited. As a result, 3H-proline incorporation
into collagen molecules and accumulation of type I collagen
were both lower in Runx2/ than in control osteoblasts (Fig-
ures 6A–6C). In contrast, when the glucose concentration in
the culture medium of Runx2/ cells reached 10 mM, the
glucose consumption rate doubled, and phosphorylation of
AMPKa1 and p70S6K, the incorporation rate of 3H-proline into
collagen molecules, and the accumulation of type I collagen
were normalized in Runx2/ cells, even though type I Collagen
gene expression did not changed (Figures 6A–6D).
In view of these results, we askedwhether chronic hyperglyce-
mia would improve bone formation in Runx2+/ embryos. This
was achieved by injecting streptozotocin (STZ; 150 mg/kg) into
Runx2+/ female mice as soon as a vaginal plug was seen. By
decreasing the number of b cells and circulating insulin levels,
this manipulation caused a severe hyperglycemia in E18.5
embryos (Figure 6E). We focused our analysis on bones forming
through intramembranous ossification because they are the
ones in which osteoblast differentiation is hampered by Runx2, Glut1ocn/, WT, and a1(I)Col-Glut1 mice (n = 8).
fl/fl, Glut1ocn/, WT, and a1(I)Col-Glut1 mice.
/, WT, and a1(I)Col-Glut1 mice (n = 10–11).
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haplo-insufficiency. While no difference was seen in WT em-
bryos carried by STZ-treated mothers (Figure S6B), alcian
blue/alizarin red staining of skeletal preparations showed that
clavicles of E18.5 Runx2+/ embryos carried by STZ-treated
mothers were twice as long as those of Runx2+/ embryos
carried by vehicle-treated mothers (1.78 ± 0.08 mm and 0.85 ±
0.05 mm). Interparietal bones were also 2-fold larger in
Runx2+/ embryos carried by STZ-treated mothers (2.09 ±
0.12 mm2 and 1.01 ± 0.13 mm2) than in those carried by control
mothers, and the fontanelles of these embryos were less open
thanwere those ofRunx2+/ embryos carried by vehicle-treated
mothers (Figures 6F and 6G). Histological analyses showed the
presence of mineralized bone trabeculae in the clavicles of
E18.5 Runx2+/ embryos carried by STZ-treated mothers (Fig-
ures 6H and 6I). An immunohistochemistry analysis showed
the presence of type I collagen molecules in the clavicles of
Runx2+/ embryos carried by STZ-treated mothers, whereas
only type X collagen molecules were present in those of
Runx2+/ embryos carried by vehicle-treated mothers (Fig-
ure 6J). Accumulation of type I collagen was also increased in
the long bones of Runx2+/ embryos carried by STZ-treated
mothers (Figures 6K and 6L). To further link the rescue of bone
phenotype in Runx2-deficient embryos to the increase in blood
glucose levels, we repeated this experiment using lower doses
of STZ (50 or 100 mg/kg). One hundred milligram per kilogram
of STZ was toxic for b cells since it decreased circulating insulin
levels nearly 2-fold without raising blood glucose levels in the
mothers or embryos (Figure 6E). This STZ dose did not correct
the delay in bone development of Runx2-deficient embryos (Fig-
ures 6F and 6G). Thus, raising blood glucose levels normalized
collagen synthesis and enhanced bone formation in Runx2+/
osteoblasts and embryos.
Although type I collagen accumulation was also normalized in
skeletal elements obtained from Runx2/ embryos carried by
STZ-treated mothers (Figure 6M), alcian blue/alizarin red stain-
ing of skeletal preparations failed to show any ECM mineraliza-
tion in the skeletons of E18.5 Runx2/ embryos carried by
STZ-treated mothers (Figure S6C). This is probably explained
by the fact that RUNX2 regulates the expression of AlkalineFigure 4. Glucose Uptake Favors Osteoblast Differentiation and Bone
(A) ADP content and ADP-to-ATP ratio in WT and Glut1/ osteoblasts (n = 6).
(B and C) AMPK, ACC1, Raptor (B), p70S6K, 4E-BP1, and eIF4G phosphorylatio
(D) Kinase assay of immune-precipitated mTORC1 complex in WT and Glut1/
(E) Raptor, p70S6K phosphorylation, and a1(I)Collagen accumulations in WT and
(F) TSC1, TSC2, and p70S6K phosphorylation, a1(I)Collagen, and RUNX2 accumu
and Tsc2 or scrambled siRNA.
(G) Expression of various AMPK subunits in osteoblasts.
(H) AMPK and p70S6K phosphorylation, RUNX2, and a1(I)Collagen accumulatio
(I and J) Alcian blue/alizarin red staining of skeletal preparations of E15.5 (I) and 1
embryos.
(K) Alcian blue staining of histological sections of femurs of E18.5 Glut1fl/fl, Glut1
(L) In situ hybridization analysis of Osteocalcin, a1(I), a1(II), and a1(X) Collage
Glut1osx/;Ampka1 osx+/ embryos.
(M) Histomorphometric analysis of L4 vertebrae of 3-month-old ofGlut1fl/fl,Glut1
(N) AMPK phosphorylation, RUNX2, and a1(I)Collagen accumulations in osteobla
(O) Histomorphometric analysis of L4 vertebrae of 3-month-old of WT mice treat
All error bars represent SEM.
See also Figure S4.
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(Murshed et al., 2005) (Figures 6D and 6N).
Crosstalk between Runx2 and Glut1 Coordinates
Osteoblast Differentiation and Bone Formation
The results presented above delineated the influence of glucose
uptake on osteoblast differentiation and bone formation but did
not explain how these two events are coordinated in vivo. In ad-
dressing this question we interpreted the fact that Glut1 expres-
sion and glucose uptake were decreased in Runx2+/ bones
(Figures 7A and 7B) as suggesting that RUNX2 regulates Glut1
expression. Runx1 expression in Glut1/a1(I) Collagen-express-
ing cells of the limb buds prompted us to test if Runx1 could
trans-activate the Glut1 promoter.
TheGlut1 promoter of themouse and other vertebrate species
has a canonical Runx binding site at 811 bp (Figure 7C). Chro-
matin immunoprecipitation assays verified that RUNX2 binds to
this site (Figure 7D), and DNA co-transfection experiments per-
formed in COS cells showed that Runx2 or Runx1 expression
vectors could increase the activity of aGlut1 promoter-luciferase
reporter construct (pGlut1-Luc) only if this site was intact (Fig-
ure 7E). In agreement with these results, expression of Glut1
was decreased in Runx2/ and increased in Schnurri-3/
osteoblasts (Shn3/) that display an increase in RUNX2 activ-
ity (Jones et al., 2006) (Figures 7F and S7A). These results explain
why glucose uptake and mTORC1 activity were decreased in
Runx2/ and increased in Shn3/ osteoblasts (Figures 6B
and 7G).
If the feedforward regulation between GLUT1-dependent
glucose uptake and RUNX2 provides an explanation for the
coordination of osteoblast differentiation and bone formation,
Glut1osx+/;Runx2+/ embryos should display a delay in osteo-
blast differentiation similar to that of Runx2/ embryos. Alcian
blue/alizarin red staining of skeletal preparations showed that
Glut1osx+/;Runx2+/ embryos were indistinguishable from
Runx2/ embryos until E16.5 (Figures 7H and S7B). At
E18.5, clavicles were barely detectable, and most of the bones
forming the skull were absent or severely hypoplastic in
Glut1osx+/;Runx2+/ embryos (Figure 7I). Alcian blue stainingFormation by Inhibiting AMPK
n in WT and Glut1/ osteoblasts.
osteoblasts (n = 3).
Raptor/ osteoblasts.
lations inWT andGlut1/ osteoblasts transfected with siRNAs targeting Tsc1
ns in Glut1fl/fl, Glut1osx/, and Glut1osx/;Ampka1osx+/ osteoblasts.
8.5 (J) Glut1fl/fl, Glut1osx/, Ampka1osx+/ and Glut1osx/;Ampka1osx+/
osx/, Ampka1osx+/, and Glut1osx/;Ampka1osx+/ embryos.
n expression in femurs of E18.5 Glut1fl/fl, Glut1osx/, Ampka1osx+/, and
ocn/, Ampka1ocn+/, andGlut1ocn/;Ampka1ocn+/male mice (n = 7–10).
sts treated with vehicle or AICAR (0.1 mM) for 16 hr.
ed with vehicle or AICAR (250 mg/kg/day) for 8 weeks (n = 6).
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of histological sections of long bones showed an enlargement
of the area of hypertrophic chondrocytes and a cartilaginous
ECM in E18.5 Glut1osx+/;Runx2+/ embryos (Figure 7J). Os-
teocalcin expression was undetectable in E18.5 Glut1osx+/;
Runx2+/ skeletal elements, while it was present in single het-
erozygous embryos. Conversely, the area covered by a1(X)
Collagen-expressing cells was greatly enlarged in E18.5
Glut1osx+/;Runx2+/ embryos (Figure 7K). The extent of the
delay in osteoblast differentiation in Glut1osx+/;Runx2+/ em-
bryos and mice explained why they all died peri-natally. This
crossregulation between Runx2 and Glut1 also determined the
extent of bone formation since 3-month-old Glut1ocn+/;
Runx2+/ mice had a low bone mass not seen in either
Glut1ocn+/ or Runx2+/ mice (Figure 7L).
Accounting for this severe phenotype, and in agreement with
the feedforward loop between glucose uptake in osteoblasts
and RUNX2, accumulation of GLUT1, type I collagen, and
RUNX2 was decreased more than 80% and phosphorylation
of AMPK and SMURF1 was increased in Glut1osx+/;
Runx2+/ compared to single heterozygous bones (Figure
7M). Hence, crossregulation of RUNX2 and Glut1 is an ampli-
fication mechanism that determines the onset of osteoblast
differentiation and the extent of bone formation throughout
life. We also treated Runx2+/ mothers with STZ (150 mg/kg)
as soon as a vaginal plug was observed. This dose of STZ
raised blood glucose levels in mothers and embryos (Figure
S7C) and increased bone formation in skeletal elements of
the skull and in clavicles in Glut1osx+/;Runx2+/ embryos
(Figure 7N).
DISCUSSION
This study identifies glucose uptake in prospective osteoblasts
as the earliest determinant of osteoblast differentiation and
bone formation. It also shows that the coordination of osteo-
blast differentiation and bone formation throughout life is main-
tained by a feedforward regulation between glucose uptake
in osteoblasts and RUNX2 accumulation. In addition, glucoseFigure 5. Runx2 Cannot Induce Proper Osteoblast Differentiation if Glu
(A) Ubiquitination of immune-precipitated RUNX2 in WT and Glut1/ osteoblas
(B) Ubiquitination of immune-precipitated RUNX2 in WT, Glut1/, Glut1/
bortezomib for 16 hr.
(C) In vitro AMPK phosphorylation assay of SMURF1 and SMURF1-S148/A.
(D) In vitro ubiquitination assay of Smurf1 and Smurf1-S148/A phosphorylated b
(E and F) RUNX2 and a1(I)Collagen accumulations, AMPK, and SMURF1 phospho
without glucose for 16 hr.
(G) Co-immunoprecipitation of AMPKa1 and SMURF1 in WT and Glut1/ oste
(H) RUNX2 and a1(I)Collagen accumulations, AMPKa1, p70S6K, and SMURF
Ampka1/ osteoblasts.
(I) RUNX2 and a1(I)Collagen accumulations and p70S6K phosphorylation in Glut
(J) 3H-proline incorporation into collagen molecules of Glut1fl/fl, Glut1/, and G
(K and L) Alcian blue/alizarin red staining of skeletal preparations of E15.5 (G)
embryos.
(M) Alcian blue staining of sections of femurs of E18.5 Glut1fl/fl, Glut1osx/, an
(N) In situ hybridization analysis of Osteocalcin, a1(I), and a1(X) Collagens expre
embryos.
(O) Schematic representation of the pathways triggered by glucose uptake in os
All error bars represent SEM.
See also Figure S5.
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homeostasis.
The Bases of the Coordination between Osteoblast
Differentiation and Bone Formation
A striking feature of bone biology that has never been explained
is that the synthesis of the main constituent of bone ECM, type I
collagen, precedes the expression of, and is not regulated by,
RUNX2, the earliest transcriptional determinant of osteoblast
differentiation. This apparent disconnect between osteoblast
differentiation and type I collagen synthesis in the bone could
be explained by a single mechanism controlling both aspects
of osteoblast biology and acting upstream of RUNX2. Our results
suggest that this is the case and that this mechanism is glucose
uptake in osteoblast progenitor cells. Glucose is the main
nutrient of osteoblasts and is taken up by these cells in an insu-
lin-independent manner through Glut1, whose expression pre-
cedes that of Runx2. Glucose uptake in osteoblasts favors
osteoblast differentiation and bone formation through two
distinct mechanisms. First, by inhibiting the activity of AMPK,
glucose uptake enhances the activity of the mTORC1 pathway
and therefore protein synthesis. Second, and unexpectedly,
glucose uptake inhibits another function of AMPK documented
here: its ability to favor RUNX2 ubiquitination in part via
SMURF1. The two distinct functions of AMPK in osteoblasts re-
vealed here explain why agonists of AMPK activity exert a dele-
terious influence on bone formation in vivo.
The Glut1-Runx2 pathway described here could have clinical
relevance. For instance, Glut1osx/ embryos develop CCD, a
disease most often caused by a decrease in RUNX2 expression.
However, a significant number of CCD patients do not have any
detectable mutations in Runx2 (Puppin et al., 2005; Tessa et al.,
2003). Conceivably, in some of these patients, CCD may be
caused by a decrease in glucose uptake or utilization in osteo-
blasts. If this were the case, it would further support the notion
that skeletal dysplasia may have a nutritional basis (Elefteriou
et al., 2006). Moreover, the predilection of osteoblasts for
glucose demonstrated here provides a plausible explanationcose Uptake Is Hampered
ts treated with 25 nM bortezomib for 16 hr.
Ampka1+/, and Glut1/ Ampka1/ osteoblasts treated with 25 nM
y AMPK.
rylation inWT, Smurf1/ (E), and Ampka1/ (F) osteoblasts cultured with or
oblasts.
1 phosphorylation in WT, Glut1/, Glut1/ Ampka1+/, and Glut1/
1fl/fl, Glut1osx/, and Glut1osx/;Smurf1+/ osteoblasts.
lut1/;Smurf1+/ osteoblasts (n = 6).
and 18.5 (I) Glut1fl/fl, Smurf1+/, Glut1osx/, and Glut1osx/;Smurf1+/
d Glut1osx /;Smurf1+/ embryos.
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for why children chronically fed a ketogenic diet experience poor
longitudinal growth (Groesbeck et al., 2006).
The Respective Functions of Glucose Uptake and Runx2
in Osteoblasts
Remarkably, restoring RUNX2 accumulation in Glut1/ cells
did not translate into efficient bone formation in vivo simply
because in osteoblasts unable to properly take up glucose, pro-
tein synthesis remains low regardless of the level of expression
of Runx2. On the other hand, raising the extracellular concentra-
tion of glucose was sufficient to initiate bone formation even
though osteoblasts were not fully differentiated inRunx2+/ em-
bryos. Raising blood glucose levels in Runx2/ embryos also
increased collagen synthesis but that did not translate into the
presence of a mineralized bone ECM because expression of
Akp2, a gene necessary for bone ECM mineralization, is low in
the absence of Runx2. Thus, RUNX2 is necessary for osteoblast
differentiation and bone ECM mineralization, but not for, para-
doxically, the synthesis of the main constituent of this ECM. In
broader terms, the importance of glucose uptake in osteoblast
differentiation described here raises the hypothesis that glucose
uptake may be a more general determinant of cell differentiation
during embryonic development. Thismay be particularly relevant
for tissue like muscle that uptakes large amounts of glucose.
Independently of its regulation of bone formation, glucose up-
take in osteoblasts is necessary for another cardinal function of
bone: the regulation of whole-body glucosemetabolism. Indeed,
through its regulation of RUNX2 accumulation, glucose favors
expression of the hormone osteocalcin.
The Synergistic Functions of Glucose Uptake and Runx2
in Osteoblasts
How is osteoblast differentiation andbone formation coordinated
throughout life? The fact that Runx2/ and Glut1/ osteo-
blasts had a similar metabolic profile suggested that this coordi-
nation might be explained if Glut1 was a target gene of RUNX2.
In support of this hypothesis, both molecular and genetic evi-
dence identifies RUNX2 as a major regulator ofGlut1 expression
and glucose uptake in osteoblasts. As a result, Runx2/ oste-
oblasts bear metabolic similarities with Glut1/ osteoblasts;
Glut1osx+/;Runx2+/ embryos are similar to Runx2/ em-Figure 6. Glucose Can Initiate Bone Formation in Runx2-Deficient Emb
(A) Glucose consumption rate in WT and Runx2/ osteoblasts cultured with 5
(B) RUNX2, a1(I)Collagen, andGLUT1 accumulations, AMPKa1, and p70S6K phos
for 14 days.
(C) 3H-proline incorporation into collagen molecules of WT and Runx2/ osteo
(D) qPCR analysis of osteoblast marker genes in WT and Runx2/ osteoblasts
(E) Blood glucose and insulin levels in STZ (50, 100, and 150 mg/kg) and vehicle
(F and G) Alcian blue/alizarin red staining of the skull (F), clavicles, and interparieta
and vehicle-treated mothers.
(H and I) Von Kossa/van Gieson staining (H) and H&E staining (I) of clavicles of E18
(J) Immunohistochemical detection of type I and type X collagens in clavicles of E1
(K) RUNX2 and a1(I)Collagen accumulations in femurs of E18.5 WT and Runx2+/
(L) a1(I) and a2(I) Collagen expression in femurs of E18.5 WT and Runx2+/ emb
(M) RUNX2 and a1(I)Collagen accumulations in femurs of E18.5 WT and Runx2
(N) Akp2 expression in femurs of E18.5 of WT and Runx2/ embryos carried b
All error bars represent SEM.
See also Figure S6.
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not seen in either Runx2+/ or Glut1ocn+/ mice. Hence, the
reciprocal regulation between GLUT1-mediated glucose uptake
and RUNX2 acts as an amplification chamber that determines
the onset of osteoblast differentiation and the extent of bone
formation throughout life. In addition, Runx1 expression in the
developing skeleton suggests that this Runx protein may regu-
late Glut1 expression and thereby favor type I collagen accumu-
lation in prospective osteoblasts before E12.5.
In broader terms, the results of this study cannot be separated
from the recently described role of osteoblasts in maintaining
glucose homeostasis in physiological and pathological situa-
tions (Lee et al., 2007; Ferron et al., 2010; Wei et al., 2014). The
absolute necessity of glucose uptake for osteoblast differentia-
tion, bone formation, and glucose homeostasis documented
here illustrates, from the perspective of osteoblasts, the funda-
mental importance of crosstalk between bone and glucose
metabolism.EXPERIMENTAL PROCEDURES
Mice Generation
To generate Glut1fl/+mice, a targeting vector harboring two LoxP sites flank-
ing exons 3–10 of Glut1 were electroporated into embryonic stem cells
(ES cells) (CSL3,129/SvEvTac) (Figure S2A). Targeted ES cells were detected
by Southern blots and injected in 129Sv/EV blastocysts to generate chimeric
mice. Chimeric mice were crossedwith Gt(ROSA)26Sortm1(FLP1)Dymmice to re-
move the Neomycin-resistance cassette and to generate Glut1fl/+ mice.
Glut1fl/+ mice were then crossed with Dermo1-Cre (Yu et al., 2003), Osterix-
Cre (Rodda and McMahon, 2006), or Ocn-Cre mice (Zhang et al., 2002) to
generate Glut1osb+/ mice, whose progenies were intercrossed to obtain
Glut1dermo1/, Glut1osx/, and Glut1ocn/ mice, respectively. To
generate a1(I)Col-Glut1 transgenic mice, a cDNA fragment of the mouse
Glut1 was cloned into a plasmid containing a 2.3-kb a1(I) collagen promoter
and microinjected using standard protocols. Ampka1fl/fl mice were obtained
from the Jackson Laboratory (Nakada et al., 2010).Runx2fl/flmicewere gener-
ated as previously described (Takarada et al., 2013). Shn3+/ and Smurf1+/
mice were generous gifts of Dr. L. Glimcher (Weill Cornell Medical College) and
Dr. J. Wrana (University of Toronto, Canada), respectively (Jones et al., 2006;
Narimatsu et al., 2009). Except for a1(I)Col-Glut1 mice, which were back-
crossed to a C57 background five times, all other mice analyzed were main-
tained on a C57/129 mixed background. Control littermates were analyzed
in all experiments. All procedures involving animals were approved by
CUMC IACUC and conform to the relevant regulatory standards.ryos
or 10 mM glucose for 16 hr.
phorylation inWT andRunx2/ osteoblasts cultured with 5 or 10mMglucose
blasts cultured with 5 or 10 mM glucose for 14 days (n = 5).
cultured with 5 or 10 mM glucose for 14 days (n = 6).
-treated Runx2+/ mothers and progenies at E18.5 (n = 5–12).
l bones (G) of E18.5 Runx2+/ embryos carried by STZ (50, 100, or 150 mg/kg)
.5 Runx2+/ embryos carried by STZ- (150 mg/kg) or vehicle-treated mothers.
8.5Runx2+/ embryos carried by STZ- (150mg/kg) or vehicle-treatedmothers.
 embryos carried by STZ- (150 mg/kg) or vehicle-treated mothers.
ryos carried by STZ- (150 mg/kg) or vehicle-treated mothers (n = 8).
/ embryos carried by STZ- (150 mg/kg) or vehicle-treated mothers.
y STZ- (150 mg/kg) or vehicle-treated mothers (n = 6).
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Cell Culture
Mouse calvaria osteoblasts were isolated and cultured as described previ-
ously (Ducy and Karsenty, 1995). Osteoclast precursors (monocytes) were iso-
lated by culturing bonemarrow cells with aMEM/10% fetal bovine serum (FBS)
containing M-CSF (10 ng/ml) for 6 days and then treated with RANKL
(30 ng/ml) and M-CSF (10 ng/ml) for 7 days. C2C12 myoblasts (ATCC), the
mHippoE-14 embryonicmouse hippocampal hypothalamic cell line (Cellutions
Biosystems), and COS-7 cells were cultured in DMEM/10% FBS. Glut1/,
Raptor/, Runx2/, Glut1/;Ampka1+/, Glut1/;Ampka1/,
Ampka1+/, and Ampka1/ calvaria osteoblasts were generated by
infecting Glut1fl/fl, Raptorfl/fl, Runx2fl/fl, Glut1fl/fl;Ampka1fl/+, Glut1fl/fl;
Ampka1fl/fl, Ampka1fl/+, or Ampka1fl/fl osteoblasts with either empty vector
or Cre-expressing adenovirus (1:800 MOI) (University of Iowa). Small inter-
fering RNAs (siRNAs) against Tsc1 and Tsc2 (Dharmacon) were transfected
to primary osteoblasts, according to the manufacturer’s protocol.
Molecular Biology and Biochemistry
For quantifying gene expression, RNA samples were extracted using TRIZOL
reagent (Invitrogen). One to two micrograms of total RNA were converted into
cDNA using M-MLV reverse transcriptase (Invitrogen). qPCR analyses were
performed using CFX-Connect real-time PCR system (Bio-Rad). Relative
expression levels of each gene were normalized to the levels of 18S rRNA or
b-actin. Western blot analyses were carried out using standard protocols. All
antibodies were obtained from Cell Signaling Technology, except for the
anti-GLUT1 (EMD Millipore), anti-COL1A1, anti-RUNX2, anti-SMURF1 (Santa
Cruz), anti-Phospho-Ser148 SMURF1 (Genescript), and anti-b-ACTIN (Sigma).
Quantification of western blots was performed using ImageJ. Protein levels
were quantified and normalized to ACTIN or GADPH levels. Relative protein
levels were calculated with respect to control samples. All western blot exper-
iments were repeated at least three times, with different samples.
Glucose Consumption and Uptake Assay
For glucose consumption measurements, following 16-hr incubation with oste-
oblasts, the glucose concentration in the culture medium was assayed with a
Glucose Assay Kit (Biovision). Glucose uptake was determined by the uptake
rate of 2-[U-14C] deoxyglucose (2-DG) in cells. Following a 1-hr fast in glucose-
free Krebs-Ringer HEPES (KRH) buffer (50 mM HEPES [pH 7.4], 136 mM NaCl,
4.7 mM KCl, 1.25 mM MgSO4, 1.25 mM CaCl2, and 0.1% BSA), cells were
cultured in KRH buffer containing 100 mM 2-deoxyglucose and 0.5 mCi/ml
2-14C-DG (287 mCi/mmol, Perkin Elmer, NEC495A) for 1 hr. For glucose uptake
in bones, 10 mCi of 2-14C-DG were immunoprecipitate injected in mice at a
random feed state for 1 hr, and calvariae were then collected for analysis. The
amountof2-14C-DG in total cell orbone lyseswasquantifiedby liquidscintillation
counter (WALLAC 1409) and normalized to protein content (Bio-Rad).
Skeleton Preparation, Bone Histology, and In Situ Hybridization
Skeleton preparations and alcian blue/alizarin red staining were carried out ac-
cording to standard protocols (McLeod, 1980). Bone histology analyses,Figure 7. The Reciprocal Regulation between Runx2 and Glut1 Determ
(A) Glut1 expression in femurs of 3-month-old Runx2+/ mice (n = 8).
(B) Uptake rate of 2-DG in the calvaria of 6-week-old WT and Runx2+/ (n = 4–5
(C) Runx binding sites in the Glut1 promoter of several species.
(D) Chromatin immunoprecipitation assay of RUNX2 binding to the promoter of m
(E) Luciferase assay of pGlut1-WT-Luc or pGlut1-mut-Luc in COS cells co-trans
(F) Expression of osteoblast marker genes in WT, Runx2/, and Shn3/ oste
(G) Glucose uptake in WT, Runx2/, and Shn3/ osteoblasts measured by th
(H and I) Alcian blue/alizarin red staining of skeletal preparations of E16.5 (H) and 18
(J) Alcian blue staining of histological sections of femurs of E18.5 Glut1osx+/, R
(K) In situ hybridization analysis of Osteocalcin, Bsp, and a1(X) Collagen express
(L) Bone histomorphometric analysis of L4 vertebrae of 3-month-old of Glut1fl/+
(M) RUNX2 and a1(I)Collagen accumulations and AMPKa1 and SMURF1 phospho
Runx2+/ embryos.
(N) Alcian blue/alizarin red staining of skeletal preparations of E18.5 Glut1osx+/;R
All error bars represent SEM.
See also Figure S7.
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histological sections of femurs or clavicle bones using standard protocols.
For all skeletal analyses, at least three litters for each embryonic stage and
at least five embryos for each genotype were examined. Bone histomorphom-
etry analyses were performed on L3 and L4 vertebrae as described previously
(Chappard et al., 1987; Parfitt et al., 1987). Von Kossa/van Gieson staining, to-
luidine blue staining, and calcein double-labeling were performed to measure
mineralized bone volume over the total tissue volume (BV/TV), osteoblast num-
ber per tissue area (N.Ob/T.Ar), mineralization apposition rate (MAR), and bone
formation rate per bone surface (BFR/BS). For in situ hybridization, tissues
were fixed in 4%paraformaldehyde/PBS overnight at 4Cand then embedded
in paraffin after dehydration and sectioned at 5 mm. In situ hybridization was
performed using 35S-labeled riboprobe as described (Ducy et al., 1997). The
Runx1, Runx3, Runx2, a1(I)Col, a 1(II)Col, a 1(X)Col, Osteocalcin, and Bsp
probes have been previously described (Takeda et al., 2001). The Glut1 probe
is a 500-bp fragment of the Glut1 30 UTR (see the Supplemental Experimental
Procedures for sequence information). Hybridizations were performed over-
night at 55C, and washes were performed at 63C.
Statistics
All data are presented as mean ± SEM. Statistical analyses were performed
using unpaired, two-tailed Student’s t test for comparison between two
groups, and an ANOVA test was used for experiments involving more than
two groups. For all experiments, * denotes p % 0.05, and # denotes p %
0.001 compared to control.
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